Aarti Drugs Limited — Call Transcript 2025

Apr 29, 2025

==> picture [516 x 97] intentionally omitted <==

Ref: ADL/SE/2025-26/05 April 29, 2025

To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Phiroze Jeejeebhoy Towers, Limited, Dalal Street, “Exchange Plaza”, Bandra - Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400051 NSE SYMBOL: AARTIDRUGS BSE CODE – 524348

Dear Sir/Madam,

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Intimation of Conference Call

This is to inform you that Quarterly Earning Conference Call for the Investors and Analysts have been scheduled on May 7, 2025 at 11:00 A.M. IST to discuss the Company’s financial performance for the Quarter ended March 31, 2025.

Please find attached herewith invitation for the same.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH Digitally signed by RUSHIKESH VIVEK DEOLE VIVEK DEOLE Date: 2025.04.29 18:42:53 +05'30' RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M.No.: F12932

==> picture [475 x 24] intentionally omitted <==

==> picture [392 x 68] intentionally omitted <==

Q4 FY25 Earnings Conference Call

DATE & TIME 7[th] May 2025 (Wednesday) 11:00 am, IST (HK/Singapore 1:30 pm, UK 6:30 am, USA 01:30 am EST)

PARTICIPANTS

• Mr. Harshit Savla – Jt. Managing Director

Mr. Harit Shah – Whole time Director

• Mr. Adhish Patil – Chief Finance Officer & Chief Operating Officer Mr. Vishwa Savla – Managing Director, Pinnacle Life Science Private Limited

PRE REGISTRATION LINK – CLICK HERE

CONFERENCE DIAL IN DETAILS

INDIA	+91 22 6280 1309 / +91 22 7115 8210
UNITED STATES	1 866 746 2133
UNITED KINGDOM	0 808 101 1573
SINGAPORE	800 101 2045
HONG KONG	800 964 448

RSVP:

Strategic Growth Advisors Pvt. Ltd.

Mr. Deven Dhruva

Contact: +91 98333 73300